Crystal Logistic signs MoU with PLUSS for COVID-19 vaccine delivery solution

Crystal Logistic Cool Chain (Crystal) has signed a Memorandum of Understanding (MoU) with Pluss Advanced Technologies (PLUSS) for the supply of indigenously developed precise temperature control boxes required of maintaining the effectiveness of the vaccine during transport. According to the MoU, PLUSS will supply its patented product – Celsure®, developed using its proprietary Phase Change Material technology, for transportation of the Covid-19 vaccines from the manufacturer to different parts of the country. Crystal specialises in refrigerated warehousing (cold storages), refrigerated transportation on a pan-India network. “Transportation of the vaccine while maintaining the precise temperature control is as important as the vaccine itself. This partnership is a very significant step towards ensuring the COVID-19 vaccine reaches its destinations in a way that maintains its efficacy,” said Samit Jain, MD, PLUSS.
While, transporting pharmaceutical products, biological products or vaccines in particular, the need to maintain precise temperature ranges is very important and the efficacy of vaccine can be impacted if the temperature goes above or below the specified range. PLUSS, an India based material solutions company has designed and manufactured a precise temperature-control delivery solution that is required for vaccine delivery to the last mile.
“Crystal Group has always been championing warehousing services and we see a major role for Crystal Logistic Cool Chain to play in transportation and storage of the COVID-19 vaccine. With PLUSS’ temperature control boxes we will ensure last mile delivery, to even the remotest parts of India,” said Akash Agarwal, CEO, Crystal Logistic Cool Chain.